Godsey & Gibb Inc’s Novo Nordisk NVO Stock Holding History

Godsey & Gibb Inc’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-133	Closed	-$9.18K	–	387
2025 Q2	$9.18K	Hold	133	–	–	﹤0.01%	262
2025 Q1	$9.24K	Hold	133	–	–	﹤0.01%	285
2024 Q4	$11.4K	Sell	133 -507	-79%	-$54.8K	﹤0.01%	263
2024 Q3	$76.2K	Buy	640 +375	+142%	+$50K	0.01%	154
2024 Q2	$37.8K	Sell	265 -265	-50%	-$35.1K	﹤0.01%	209
2024 Q1	$68.1K	Sell	530 -60	-10%	-$7.14K	0.01%	146
2023 Q4	$61K	Hold	590	–	–	0.01%	147
2023 Q3	$53.7K	Sell	590 -30	-5%	-$2.64K	0.01%	152
2023 Q2	$50.2K	Hold	620	–	–	0.01%	167
2023 Q1	$49.3K	Sell	620 -40	-6%	-$2.84K	0.01%	166
2022 Q4	$44.7K	Buy	+660	New	+$38.7K	0.01%	126
2022 Q1	–	Sell	-660	Closed	-$37K	–	135
2021 Q4	$37K	Buy	+660	New	+$35.8K	0.01%	59
2021 Q3	–	Sell	-1,320	Closed	-$55K	–	120
2021 Q2	$55K	Buy	+1,320	New	+$51.2K	0.03%	41

Other funds holding NVO

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Godsey & Gibb Inc's NVO Position: Q3 2025 in Review

Godsey & Gibb Inc sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 133 shares — an estimated $9.18K sold.

Godsey & Gibb Inc first reported a position in NVO in Q2 2021 and held it in 13 quarters. The position peaked at $76.2K in Q3 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

Godsey & Gibb Inc reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
Godsey & Gibb Inc sold 133 Novo Nordisk shares in Q3 2025, an estimated $9.18K.
Godsey & Gibb Inc first reported a position in Novo Nordisk in Q2 2021 and held it in 13 quarters.
Godsey & Gibb Inc's Novo Nordisk position peaked at $76.2K in Q3 2024.
1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Godsey & Gibb Inc's 13F filing for Q3 2025, filed 24 Oct 2025.